Equities

Mirum Pharmaceuticals Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Mirum Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)86.30
  • Today's Change-1.54 / -1.75%
  • Shares traded599.51k
  • 1 Year change+98.76%
  • Beta0.5279
Data delayed at least 15 minutes, as of Mar 06 2026 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Mirum Pharmaceuticals Inc grew revenues 54.74% from 336.89m to 521.31m while net income improved from a loss of 87.94m to a smaller loss of 23.36m.
Gross margin80.77%
Net profit margin-4.48%
Operating margin-4.25%
Return on assets-3.09%
Return on equity-8.65%
Return on investment-3.96%
More ▼

Cash flow in USDView more

In 2025, Mirum Pharmaceuticals Inc increased its cash reserves by 33.75%, or 75.24m. The company earned 55.83m from its operations for a Cash Flow Margin of 10.71%. In addition the company generated 40.14m cash from financing while 23.95m was spent on investing.
Cash flow per share0.017
Price/Cash flow per share5,910.88
Book value per share6.06
Tangible book value per share1.04
More ▼

Balance sheet in USDView more

Mirum Pharmaceuticals Inc has a Debt to Total Capital ratio of 49.61%, a lower figure than the previous year's 136.54%.
Current ratio2.67
Quick ratio2.55
Total debt/total equity0.9845
Total debt/total capital0.4961
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.